The Incorrect Statement is E
Statement E is incorrect: Central diabetes insipidus (CDI) typically DOES require specific treatment with desmopressin (DDAVP) in most patients, contrary to the claim that it "usually does not require specific treatment." 1
Analysis of Each Statement
Statement A - CORRECT
CDI is indeed characterized by antidiuretic hormone (AVP/ADH) deficiency, resulting in the classic triad of hypotonic polyuria and compensatory polydipsia 2, 3. This is the fundamental pathophysiology of the condition.
Statement B - CORRECT
Hypernatremia is a significant risk when patients cannot maintain adequate water intake to compensate for renal water losses 2. This is particularly dangerous in:
- Patients with impaired consciousness
- Those with adipsic diabetes insipidus (loss of thirst mechanism) 4, 5
- Situations where access to water is restricted
Statement C - CORRECT
CDI is classified into three main subtypes 3:
- Primary (idiopathic): Often related to infundibuloneurohypophysitis
- Secondary: Due to tumors (craniopharyngioma, germ cell tumors), trauma, surgery, or autoimmune destruction
- Familial: Autosomal dominant inheritance with >80 mutations in the AVP gene locus
Statement D - CORRECT with Important Caveats
While clinical presentation (polyuria, polydipsia) raises suspicion, the diagnosis requires biochemical confirmation 6, 2, 7. The diagnostic approach includes:
- Urine osmolality measurement (typically <300 mOsm/kg)
- Water deprivation test (gold standard, though with interpretative pitfalls)
- Copeptin assay (emerging as superior diagnostic tool) 6
- Response to desmopressin administration
The statement is technically correct because diagnosis begins clinically, but biochemical testing is essential for confirmation.
Statement E - INCORRECT
The Endocrine Society guidelines explicitly recommend offering DDAVP therapy to all patients with CDI 1. Key treatment principles include:
- Individualized DDAVP dosing schedules are recommended for all patients
- Some patients with partial CDI may decline treatment if minimally symptomatic, but this is patient preference, not standard practice
- Most patients require treatment to prevent:
- Severe hypernatremia
- Volume depletion
- Impaired quality of life from constant polyuria/polydipsia
Critical Management Points
Treatment essentials 1:
- Educate patients about hyponatremia risk from DDAVP overdosing
- Patients should experience at least weekly "breakthrough" polyuria to confirm medication has worn off
- Post-surgical CDI: Attempt DDAVP discontinuation to assess for recovery of posterior pituitary function
- Emergency identification: All CDI patients should wear medical alert bracelets 1
Special consideration for adipsic CDI 1, 4:
- Requires meticulous DDAVP and fluid titration
- Daily weight monitoring essential
- Frequent sodium level checks
- Higher morbidity and mortality risk
The claim that CDI "usually does not require specific treatment" contradicts established guidelines and clinical practice, making statement E definitively incorrect.